Climb Bio (CLYM) Competitors

Tectonic Therapeutic (NASDAQ:TECX) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Do institutionals & insiders have more ownership in TECX or CLYM?

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 9.2% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 3.2% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, TECX or CLYM?

Tectonic Therapeutic has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.

Do analysts recommend TECX or CLYM?

Tectonic Therapeutic currently has a consensus price target of $77.75, suggesting a potential upside of 316.89%. Climb Bio has a consensus price target of $10.00, suggesting a potential upside of 681.25%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Climb Bio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Is TECX or CLYM more profitable?

Tectonic Therapeutic's return on equity of -35.53% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.53%	-31.97%
Climb Bio	N/A	-42.21%	-41.39%

Does the MarketBeat Community prefer TECX or CLYM?

Tectonic Therapeutic received 7 more outperform votes than Climb Bio when rated by MarketBeat users.

Company	Underperform	Outperform
Tectonic Therapeutic	Outperform Votes 9 100.00%	Underperform Votes No Votes
Climb Bio	Outperform Votes 2 100.00%	Underperform Votes No Votes

Which has stronger valuation & earnings, TECX or CLYM?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	$12.16M	-$6.53	-2.86
Climb Bio	N/A	N/A	-$35.12M	-$2.13	-0.60

Does the media refer more to TECX or CLYM?

In the previous week, Climb Bio had 8 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 13 mentions for Climb Bio and 5 mentions for Tectonic Therapeutic. Climb Bio's average media sentiment score of 0.87 beat Tectonic Therapeutic's score of 0.66 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic and Climb Bio tied by winning 7 of the 14 factors compared between the two stocks.